Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

Human Gene Therapy

Volumn 12, Issue 3, 2001, Pages 253-265

  Wong, R J ^a   Patel, S G ^a   Kim, S H ^a,b   DeMatteo, R P ^a   Malhotra, S ^a   Bennett, J J ^a   St Louis, M ^c   Shah, J P ^a   Johnson, P A ^c   Fong, Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c Neurovir   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; GENE TRANSFER; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR VOLUME; VIRUS REPLICATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-12; LAC OPERON; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C3H; MODELS, GENETIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLASMIDS; SIMPLEXVIRUS; TIME FACTORS;

ANIMALIA; HERPES; HERPESVIRIDAE; MURINAE; SIMPLEXVIRUS;

EID: 20244374204     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340150218396     Document Type: Article

References (49)

1. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
2. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes
3. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
4. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
5. Antitumor and antimetastatic activity of interleukin-12 against routine tumors
6. Selective infection and cyrolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type I (G207)
7. Induction of interferon gamma production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers
8. 134.5, a gene nonessential for growth in culture
9. 134.5-mutants of herpes simplex virus 1
10. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
11. In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors
12. Modification of the effects of continuous low-dose radiation by concurrent chemotherapy infusion
13. A defective HSV-1 vector expresses Escherichia coli-galactosidase in cultured peripheral neurons
14. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by doublestranded RNA-activated protein kinase
15. A routine model for the immunotherapy of head and neck squamous cell carcinoma
16. Development of TH 1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages
17. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
18. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-I (G207)
19. In vivo depletion of CD4- and CD8-specific T cells
20. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors
21. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene
22. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant vaccine
23. The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene
24. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12
25. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
26. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
27. Attenuated multi-mutated herpes simplex virus- 1 for the treatment of malignant gliomas
28. Structure of the chromosomal gene for granulocytemacrophage colony stimulating factor: Comparison of the mouse and human genes
29. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice
30. CD8+ T cells infiltrated within cancer nests as a prognostic factor in human colorectal cancer
31. A new immunocompetent murine model for oral cancer
32. Mechanisms of immune suppression in patients with head and neck cancer: Presence of CD45(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor
33. Paracrine cytokine adjuvants in cancer immunotherapy
34. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
35. Genetic engineering of novel genomes of large DNA viruses
36. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
37. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
38. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
39. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
40. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus
41. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer
42. Granulocytemacrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma
43. Broadened clinical utility of gene gun-mediated granulocyte-macrophage colony stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model
44. Inhibition of anglogenesis in vivo by interleukin 12
45. Head and neck cancer
46. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
47. IL-12 induces human T cells secreting IL-10 with IFN-gamma
48. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes